Pharmacyclics, Inc. today announced that the U.S. Food and Drug Administration has approved IMBRUVICA ) as a single agent for the treatment of patients with chronic lymphocytic leukemia who have received at least one prior therapy.
http://ift.tt/1j5BbuO
http://ift.tt/1j5BbuO
No comments:
Post a Comment